gastrointestinal stromal tumors
GPTKB entity
Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Oncology
|
gptkbp:associated_with |
gastrointestinal tract
|
gptkbp:characterized_by |
mutations in KIT or PDGFRA genes
|
gptkbp:clinical_trial |
ongoing studies
phase II trials phase III trials |
gptkbp:death |
approximately 5-year survival rate varies
higher in localized disease lower in metastatic disease |
gptkbp:demographics |
more common in adults
rare in children |
gptkbp:diagnosis |
gptkb:MRI
CT scan biopsy endoscopy depends on tumor size and mitotic index |
gptkbp:diseases |
epithelioid type
mixed type spindle cell type |
gptkbp:events |
clinical evaluations
regular imaging studies |
gptkbp:financial_support |
counseling services available
educational resources available support groups available |
gptkbp:genetic_studies |
gain-of-function mutations
|
gptkbp:genetic_syndrome_association |
associated with Carney-Stratakis syndrome
associated with familial GIST syndrome |
gptkbp:historical_context |
first described in 1983
previously thought to be leiomyomas recognized as distinct entity in 2000s |
https://www.w3.org/2000/01/rdf-schema#label |
gastrointestinal stromal tumors
|
gptkbp:imaging_findings |
may have calcifications
may have necrosis may show heterogeneous enhancement |
gptkbp:is_located_in |
stomach
small intestine |
gptkbp:occurs_in |
approximately 10-20 per million people
|
gptkbp:origin |
gptkb:interstitial_cells_of_Cajal
|
gptkbp:research_focus |
biomarkers
targeted therapies genetic profiling |
gptkbp:risk_factor |
gptkb:neurofibromatosis_type_1
gptkb:Carney_triad age family history of GIST |
gptkbp:scientific_classification |
benign
malignant |
gptkbp:symptoms |
gptkb:anemia
nausea abdominal pain vomiting |
gptkbp:treatment |
gptkb:imatinib
gptkb:sunitinib gptkb:surgery variable response to therapy |
gptkbp:treatment_resistance |
can develop resistance to imatinib
can develop resistance to sunitinib |
gptkbp:bfsParent |
gptkb:Gleevec
|
gptkbp:bfsLayer |
5
|